PubMed COVID-19 Clinical Care

No abstract

CONCLUSIONS: In our population, recovery from COVID-19 was associated with increased Q(S)/Q(t) in 37% of patients, increased V(D)/V(T) in 86%, and increased alveolar ventilation up to ~13 months post infection. NIH severity predicted Q(S)/Q(t) but

Creativity can function as a catalyst for social development; however, it also possesses a destructive potential. In recent years, scholars have discovered that creativity harbors a dark side, counterbalancing its positive aspects. This study aims to

Following vaccination with adenoviral vector-based ChAdOx1 nCoV-19, serious neurological adverse events have been reported. Here we report two cases who presented with quadriparesis following the adenoviral vector-based ChAdOx1 nCoV-19 vaccine. A 55

The global pandemic forced young adults and their parents to be together. This situation has equally exposed the weaknesses in the child-parent relationship. This study aimed to investigate the role of social intelligence in the relationship between

Atrial fibrillation (AF) is a rare complication of multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 10-year-old boy with a history of SARS-CoV-2 infection

Background: Sentinel lymph node biopsy (SLNB) is now the gold standard for early breast cancer with clinically negative lymph nodes (N0). According to the Indonesian Board-Certified oncologist surgeon, the learning curve for evaluating fellow breast

The global research community responded with speed and at scale to the emergence of COVID-19, with around 4.6% of all research outputs in 2020 related to the pandemic. That share almost doubled through 2021, to reach 8.6% of research outputs. This

The long-term effects of COVID-19 on cognitive function have become an area of increasing concern. This paper provides an overview of characteristics, risk factors, possible mechanisms, and management strategies for cognitive dysfunction in post

Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the